Umifenovir is commonly used for the treatment and prophylaxis of Influenza A and Influenza B infections, alongside other Acute Respiratory Viral Infections (ARVI). This therapeutic domain covers acute conditions marked by the sudden onset of heightened symptomatic discomfort. The use of Umifenovir generally helps to ease the overall symptom burden and contributes to easing the overall duration of the symptomatic period.

---

The medication is relevant in clinical settings where key symptoms, such as fever, generalized malaise, and cough, create noticeable physiological strain. It is commonly used to help with symptom clusters that may become intense or disruptive, assisting with maintaining a sense of stability during symptomatic periods. This usage is particularly relevant during seasonal epidemic risk.

“This medication is applied in settings where additional management of discomfort is required during acute symptomatic episodes.”

Umifenovir is applied in addressing conditions presenting with acute episodes and recurrent manifestations, including Influenza A, Influenza B, and ARVI. It contributes to easing the overall symptom burden and may assist in reducing the risk associated with contracting a viral illness or developing associated symptomatic manifestations.

---

Quick Fact: Support in Acute Symptomatic Contexts

Benefit Focus	Therapeutic Domain
Symptom Management	Assists with maintaining a sense of stability during symptomatic periods.
Use Context	Relevant in contexts involving heightened systemic burden and acute symptoms.
Patient Benefit	Provides support that helps ease the overall symptom burden.

Eligibility for Umifenovir (Арбидол) is determined by its official prescribing information, which outlines absolute prohibitions and conditional limitations across different patient populations.

Absolute Contraindications

Use of the medicine is strictly prohibited for the following populations as defined in regulatory documents:

• Hypersensitivity: Patients with known allergy or hypersensitivity to Umifenovir or any other component of the specific formulation.
• Pregnancy and Lactation: Use is contraindicated during the first trimester of pregnancy and throughout the entire breastfeeding period.
• Metabolic Disorders: Contraindicated in patients with specific inherited metabolic conditions, such as glucose-galactose malabsorption or sucrose/isomaltose deficiency, due to excipients in certain dosage forms.

Age and Conditional Restrictions

The approved age for use varies based on the product formulation, with different minimum age thresholds (e.g., 2 years, 3 years, 6 years, or 12 years) for suspension, tablets, or capsules.

Use is subject to special medical caution and oversight in patients with the following conditions:

• Severe Organ Impairment: The drug's effectiveness and safety have not been formally evaluated in individuals with severe hepatic impairment or renal impairment, requiring caution during prescription.

Interactions with other medicines and products

The official regulatory profile for Arbidol (Umifenovir) regarding drug interactions is primarily characterized by an absence of documented negative interactions with specific categories of co-administered medicines.

Official Regulatory Interaction Statements

Interaction Type	Regulatory Status/Findings
Drug-Drug Contraindications	No absolute drug-drug contraindications are explicitly listed in official regulatory texts.
Pharmacodynamic Interactions	Regulatory documents note that no undesirable interactions were found when Arbidol was co-administered with common symptomatic therapies, including antipyretic (fever-reducing), mucolytic, and local vasoconstrictor medicines.
Pharmacokinetic Basis (CYP/Transporters)	Information on specific cytochrome P450 (CYP) enzyme-mediated or drug transporter interactions is not documented in the official labeling.
Food/Alcohol/Herbal Products	No specific clinically significant interactions with food, alcohol, or herbal products are documented.

Summary of Interaction Profile

The interaction structure of Arbidol, as defined by the official labeling, relies on statements of non-incompatibility with common symptomatic medicines rather than a comprehensive list of known interaction risks or mechanisms. Regulatory texts explicitly acknowledge that dedicated clinical studies to investigate the interactions of Arbidol with other specific medicinal products have not been conducted. Therefore, the official documentation does not impose specific restrictions on co-administration timing or dose separation with other medications.

Umifenovir ( Арбидол) operates through a dual mechanistic approach, targeting both viral propagation and the host's innate immune system, resulting in a combined molecular consequence that restricts viral spread and supports host defense signaling.

Blockade of Viral Fusion and Entry

Umifenovir functions as a fusion inhibitor by interacting with the viral envelope and the host cell's endosome membrane. In the case of influenza, it binds to the Hemagglutinin (HA) protein, stabilizing its pre-fusion state and preventing the pH-dependent conformational changes necessary for the virus to merge with the host cell. This mechanism stops the transfer of viral genetic material into the host cell cytoplasm, leading to the cessation of early viral replication and limiting the progression of systemic viral propagation.

Modulation of Innate Immune Defense Pathways

This molecule modulates the innate immune system by stimulating the production of Interferons (IFN-alpha/IFN-gamma) and increasing the activity level of macrophage phagocytic function. Furthermore, it can influence specific intracellular signaling cascades, such as the p38 MAPK pathway, which affects the expression of immunosuppressive cytokines. This concerted action results in the physiological consequence of augmented phagocytic activity and robust activation of the host's antiviral defense signaling.

The administration of Umifenovir (Арбидол) is defined by structured protocols that specify the route, dose, frequency, and duration of intake, strictly as outlined in official pharmaceutical documentation. The medicine is administered exclusively by the oral route, typically supplied as hard capsules or tablets in strengths such as 50 mg or 100 mg.

Official usage is segregated into regimens for acute treatment and for prophylaxis. For the acute treatment of viral infection, the typical adult and pediatric regimen for children over two years involves administering 50 mg to 200 mg of Umifenovir per dose. This dosage is taken four times daily (e.g., every six hours) over a fixed duration of five consecutive days.

Conversely, the protocol for prophylactic use, such as following known exposure to an infected person, involves a different frequency and a longer duration. For this purpose, the medicine is typically administered once per day for a course lasting from 10 to 14 days.

Regarding administration conditions, a key instruction is that the drug's bioavailability is not dependent on food intake, permitting flexible administration time before, during, or after meals. Use is restricted to patients two years of age and older, as standardized instructions do not permit administration to younger children.

Umifenovir, known commercially as Arbidol, is a broad-spectrum antiviral agent approved and used in Russia and China for the prophylaxis and treatment of influenza and other acute respiratory viral infections (ARVI). Its primary mechanism of action involves inhibiting the fusion of the viral envelope with the cell membrane, preventing the virus from entering the host cell. The drug is also noted to possess immunomodulatory properties that enhance the body's non-specific immune defenses.

Clinical Efficacy in Influenza and ARVI

Clinical trials have long supported the use of umifenovir in treating influenza, with evidence suggesting that when administered in the acute stage of the disease, it can reduce the duration and severity of symptoms and decrease the time of viral shedding.

Viral Target	Established Efficacy	Regulatory Status
Influenza A & B	Demonstrated reduction in symptom severity and duration of illness.	Approved in Russia and China.
Other ARVI	Some clinical use for treatment and prophylaxis.	Approved in Russia and China.

Evidence in Novel Coronaviruses (e.g., COVID-19)

Following the emergence of SARS-CoV-2, umifenovir was investigated in numerous clinical trials for its potential use against COVID-19, based on in vitro data suggesting antiviral activity against coronaviruses. The overall clinical consensus on its effectiveness against COVID-19 remains controversial and is not universally established by major international health authorities.

• Select Studies: Some randomized and retrospective studies, predominantly conducted early in the pandemic, indicated that umifenovir might be associated with a faster resolution of clinical symptoms or improvement in lung CT scan scores in patients with mild to moderate disease. For example, one meta-analysis indicated a potential benefit in the rate of clinical improvement and duration of fever.
• Overall Findings: However, a systematic review and meta-analysis of multiple trials did not establish a significant difference between umifenovir and non-antiviral treatments regarding key patient-important outcomes such as the rate of viral clearance, length of hospital stay, or mortality. Consequently, its routine use for COVID-19 treatment is generally not justified by current comprehensive evidence, and further high-quality randomized controlled studies are needed to conclusively determine its efficacy and safety against new and emerging acute respiratory viral infections.

Common questions about Арбидол (FAQ)

Q: How should I store this medication?

Official product information provides specific guidelines for storing this medicine to maintain its stability. It should be kept at the specified temperature range, such as in a cool, dry place. Patients should reference the official label or leaflet for the precise storage details, including instructions on keeping the medicine away from moisture and light.

Q: Can I drink alcohol while taking this medicine?

Regulatory information addresses the combined use of this medicine and alcohol. The official product information often indicates that combining the two may be contraindicated or could increase the risk of certain side effects, such as heightened drowsiness or potential problems affecting the liver. This information is detailed in the official warnings section of the regulatory label.

Q: Does it make you sleepy or affect my ability to drive?

Regulatory documents report that side effects like dizziness, somnolence (drowsiness), or sedation have been associated with this medicine. Regulatory documents indicate that this medicine may impair the abilities required for driving or operating machinery, and patients should be aware of this possibility.

Q: Who should not take this medicine? (e.g., contraindications)

The official label specifies 'contraindications,' which are factors that make it inappropriate to take the medicine. Regulatory labels state this medicine is contraindicated in people with a known history of hypersensitivity or allergic reaction to the active substance or its ingredients. The label also lists specific pre-existing medical conditions that exclude its use.

Q: Is it safe long-term?

Official regulatory information includes warnings and precautions regarding the safety profile over extended treatment duration. The label may address specific risks that can potentially increase with prolonged use of the medicine. Furthermore, the label may indicate that monitoring or check-ups are relevant during extended treatment periods to manage these risks.

Q: Can children 2 years old use it?

The official product information defines the approved age range for use of this drug. It specifies the minimum age for the pediatric population, or it states where safety and effectiveness have not been established. Patients should consult the official label to confirm the indicated ages.

How to Store and Dispose of Арбидол?

The storage and disposal of Umifenovir (Арбидол) are subject to official regulatory requirements to maintain product stability and ensure public safety.

Storage Constraints

Product Form	Temperature Constraint	Stability Period
Capsules / Tablets	Not above 25 C	Up to 3 years
Prepared Suspension	Not above 8 C (Refrigerated)	10 days after preparation

Solid dosage forms must be kept in their original packaging, protected from both light and moisture. The prepared liquid suspension must not be frozen and is only stable under refrigeration for ten days. All forms must be stored in a place inaccessible to children and must not be used after the expiration date.

Disposal Rules

Disposal of unused or expired Umifenovir must be done in accordance with local regulatory procedures. Official instructions mandate that the medicine not be thrown into household waste or wastewater.